Sep 13, 2022 / 02:30PM GMT
Jason Shieh - H.C. Wainwright & Co. - Analyst
Hello, everyone, and thank you for joining the H.C. Wainwright 24th Annual Global Investment Hybrid Conference. My name is Jason Shieh, and I'm a H.C. Wainwright healthcare research associate. I'd like to welcome our next speaker, Michael Breen, Interim CEO, Executive Chairman, Board of Directors; and Gavin Choy, Chief Clinical Development Officer of GT Biopharma, a clinical stage immuno-oncology company, focused on developing innovative therapeutic based on proprietary natural killer cell engager known as TriKE. And thank you, gentlemen.
Michael Breen - GT Biopharma, Inc. - Executive Chairman & Interim CEO
Thank you, Jason. Good morning, everyone, and thank you for taking the time to join us this morning and listen to our presentation. Much appreciated. And if I can just take you through the first forward-looking statement, which is our standard form disclaimer. I'll not bore you with the minutiae [set out in this], but if you just all please take time to read through that, that would be helpful.
GT Biopharma Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
